US 11,718,683 B2
Antigen-binding fusion proteins with modified HSP70 domains
Timothy Brauns, Brookline, MA (US); Mark C. Poznansky, Newton Center, MA (US); Jeffrey A. Gelfand, Cambridge, MA (US); Huabiao Chen, Winchester, MA (US); and Stephen J. McCormack, Las Vegas, NV (US)
Assigned to Aperisys, Inc., Cumming, GA (US); and The General Hospital Corporation, Boston, MA (US)
Filed by The General Hospital Corporation, Boston, MA (US); and Apensys, Inc., Cumming, GA (US)
Filed on Aug. 5, 2019, as Appl. No. 16/532,200.
Application 16/532,200 is a continuation of application No. 15/456,196, filed on Mar. 10, 2017, abandoned.
Claims priority of provisional application 62/306,168, filed on Mar. 10, 2016.
Prior Publication US 2020/0095332 A1, Mar. 26, 2020
Int. Cl. C07K 16/30 (2006.01); C07K 14/35 (2006.01); C07K 19/00 (2006.01); A61K 39/00 (2006.01); A61K 38/00 (2006.01)
CPC C07K 16/3069 (2013.01) [C07K 14/35 (2013.01); C07K 16/30 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 19/00 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C07K 2319/70 (2013.01); C07K 2319/74 (2013.01)] 7 Claims
 
1. A fusion protein comprising an antibody or antigen-binding fragment thereof fused in frame to a fragment of Mycobacterium tuberculosis heat shock protein 70 (HSP70) of less than 200 amino acids, wherein the fragment of HSP70 comprises a minimal HSP70 sequence, wherein the fragment of HSP70 comprises a modified CD94 domain consisting of the amino acid sequence of
 
 (SEQ ID NO: 16)
 
 AAHNNLLGSFELTG; 
 
 
 
 (SEQ ID NO: 17)
 
 AAHNNLLGRFELTG; 
 
 
 
 (SEQ ID NO: 18)
 
 AAHNNLLGRFELSG; 
 
 
 
 (SEQ ID NO: 19)
 
 TKENNLLGRFELSG; 
 
 [[or]]
 
 and 
 
 
 
 (SEQ ID NO: 20)
 
 TRDNNLLGRFELSG. 
and
wherein the fusion protein comprises the amino acid sequence of SEQ ID SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, or SEQ ID NO:31.